SCHEMBL20127045

SCHEMBL20127045

CC(C)(C)NC(=O)c1cc(-c2ccc(F)c(F)c2)nc(-n2ccnc2C(C)(C)C)c1

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMO O15229 2/20 0.37
RIPK1 Q13546 1/20 0.36
NAMPT P43490 1/20 0.36
ALOX5AP P20292 4/20 0.35
FEN1 P39748 4/20 0.35
KDM5A P29375 1/20 0.34
KDM4C Q9H3R0 1/20 0.34
KDM5B Q9UGL1 1/20 0.34
HDAC2 Q92769 1/20 0.34
MPL P40238 1/20 0.34
CNR1 P21554 1/20 0.33
ALDH1A1 P00352 1/20 0.33
POLB P06746 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
ANO1 Q5XXA6 2/20 0.33
WNT3A P56704 1/20 0.33
CSNK1E P49674 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18389615 0.92 CSNK1D (0.37) RIPK1CSNK1E
SCHEMBL18389327 0.90 MAPT (0.39) RIPK1NAMPTALOX5APFEN1ALDH1A1
SCHEMBL18389322 0.88 CNR1 (0.43) RIPK1NAMPTCNR1
SCHEMBL20127046 0.87 RIPK1 (0.38) RIPK1ALDH1A1ANO1
SCHEMBL18389397 0.86 P2RY14 (0.42) RIPK1ALOX5APFEN1KDM4CALDH1A1
SCHEMBL18389521 0.84 NPC1 (0.45) HDAC2ALDH1A1POLBTDP1
SCHEMBL21004125 0.84 RIPK1 (0.36) RIPK1CNR1ALDH1A1POLB
SCHEMBL18389351 0.83 EGLN1 (0.44) RIPK1ALDH1A1ANO1
SCHEMBL18389457 0.83 MAPT (0.38) RIPK1NAMPTALOX5APFEN1ALDH1A1
SCHEMBL18389614 0.82 P2RY14 (0.37) RIPK1KDM4CHDAC2CSNK1E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107709311-B 2-phenyl-6-imidazolyl-pyridine-4-carboxamide derivatives and their use as EAAT3 inhibitors 豪夫迈·罗氏有限公司 2020-09-25 CN claimed
EP-3322699-B1 2-PHENYL-6-IMIDAZOLYL-PYRIDINE-4-CARBOXAMIDE DERIVATIVES AND THEIR USE AS EAAT3 INHIBITORS HOFFMANN LA ROCHE (CH) 2019-05-15 EP claimed
CN-107709311-B 2-phenyl-6-imidazolyl-pyridine-4-carboxamide derivatives and their use as EAAT3 inhibitors 豪夫迈·罗氏有限公司 2020-09-25 CN disclosed
EP-3322699-B1 2-PHENYL-6-IMIDAZOLYL-PYRIDINE-4-CARBOXAMIDE DERIVATIVES AND THEIR USE AS EAAT3 INHIBITORS HOFFMANN LA ROCHE (CH) 2019-05-15 EP disclosed
US-20180125823-A1 IMIDAZOLE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2018-05-10 US disclosed
US-20180125823-A1 IMIDAZOLE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2018-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180125823-A1 IMIDAZOLE DERIVATIVES OXTR, DRD3, MC3R KMO 229/4885RIPK1 1705/4885NAMPT 4297/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.